346 related articles for article (PubMed ID: 34372950)
1. SARS-CoV-2 outbreak in a synagogue community: longevity and strength of anti-SARS-CoV-2 IgG responses.
Gozlan Y; Reingold S; Koren R; Halpern O; Regev-Yochay G; Cohen C; Biber A; Picard O; Mendelson E; Lustig Y; Mor O
Epidemiol Infect; 2021 Jun; 149():e153. PubMed ID: 34372950
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies.
Rychert J; Couturier MR; Elgort M; Lozier BK; La'ulu S; Genzen JR; Straseski JA; Delgado JC; Slev PR
J Appl Lab Med; 2021 Apr; 6(3):614-624. PubMed ID: 33064790
[TBL] [Abstract][Full Text] [Related]
3. Antibody response using six different serological assays in a completely PCR-tested community after a coronavirus disease 2019 outbreak-the CoNAN study.
Weis S; Scherag A; Baier M; Kiehntopf M; Kamradt T; Kolanos S; Ankert J; Glöckner S; Makarewicz O; Hagel S; Bahrs C; Kimmig A; Proquitté H; Guerra J; Rimek D; Löffler B; Pletz MW;
Clin Microbiol Infect; 2021 Mar; 27(3):470.e1-470.e9. PubMed ID: 33221432
[TBL] [Abstract][Full Text] [Related]
4. Seroprevalence and humoral immune durability of anti-SARS-CoV-2 antibodies in Wuhan, China: a longitudinal, population-level, cross-sectional study.
He Z; Ren L; Yang J; Guo L; Feng L; Ma C; Wang X; Leng Z; Tong X; Zhou W; Wang G; Zhang T; Guo Y; Wu C; Wang Q; Liu M; Wang C; Jia M; Hu X; Wang Y; Zhang X; Hu R; Zhong J; Yang J; Dai J; Chen L; Zhou X; Wang J; Yang W; Wang C
Lancet; 2021 Mar; 397(10279):1075-1084. PubMed ID: 33743869
[TBL] [Abstract][Full Text] [Related]
5. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
6. Pre-pandemic antibodies screening against SARS-CoV-2 and virus detection among children diagnosed with eruptive fevers.
Najimi N; Tajount L; Regragui Z; Remz C; Ait-Lhaj-Mhand R; Kadi C; Belayachi L; Seghrouchni F; Nadia Dakka ; El Hassani RA; Elharti E; Oumzil H; Bakri Y
Int J Immunopathol Pharmacol; 2024; 38():3946320241260633. PubMed ID: 38836458
[TBL] [Abstract][Full Text] [Related]
7. Characteristics of Anti-SARS-CoV-2 Antibodies in Recovered COVID-19 Subjects.
Huynh A; Arnold DM; Smith JW; Moore JC; Zhang A; Chagla Z; Harvey BJ; Stacey HD; Ang JC; Clare R; Ivetic N; Chetty VT; Bowdish DME; Miller MS; Kelton JG; Nazy I
Viruses; 2021 Apr; 13(4):. PubMed ID: 33923828
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) cPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G Commercial Serology Assays.
Nandakumar V; Profaizer T; Lozier BK; Elgort MG; Larragoite ET; Williams ESCP; Solis-Leal A; Lopez JB; Berges BK; Planelles V; Rychert J; Slev PR; Delgado JC
Arch Pathol Lab Med; 2021 Oct; 145(10):1212-1220. PubMed ID: 34181714
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 Seroprevalence Structure of the Russian Population during the COVID-19 Pandemic.
Popova AY; Smirnov VS; Andreeva EE; Babura EA; Balakhonov SV; Bashketova NS; Bugorkova SA; Bulanov MV; Valeullina NN; Vetrov VV; Goryaev DV; Detkovskaya TN; Ezhlova EB; Zaitseva NN; Istorik OA; Kovalchuk IV; Kozlovskikh DN; Kombarova SY; Kurganova OP; Lomovtsev AE; Lukicheva LA; Lyalina LV; Melnikova AA; Mikailova OM; Noskov AK; Noskova LN; Oglezneva EE; Osmolovskaya TP; Patyashina MA; Penkovskaya NA; Samoilova LV; Stepanova TF; Trotsenko OE; Totolian AA
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452512
[TBL] [Abstract][Full Text] [Related]
10. Symptoms and immunoglobulin development in hospital staff exposed to a SARS-CoV-2 outbreak.
Brandstetter S; Roth S; Harner S; Buntrock-Döpke H; Toncheva AA; Borchers N; Gruber R; Ambrosch A; Kabesch M
Pediatr Allergy Immunol; 2020 Oct; 31(7):841-847. PubMed ID: 32413201
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
Marklund E; Leach S; Nyström K; Lundgren A; Liljeqvist JÅ; Nilsson S; Yilmaz A; Andersson LM; Bemark M; Gisslén M
Front Immunol; 2021; 12():750448. PubMed ID: 34795668
[TBL] [Abstract][Full Text] [Related]
12. Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection.
Kučinskaitė-Kodzė I; Simanavičius M; Šimaitis A; Žvirblienė A
Viruses; 2021 Nov; 13(11):. PubMed ID: 34835119
[TBL] [Abstract][Full Text] [Related]
13. Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients.
Luchsinger LL; Ransegnola BP; Jin DK; Muecksch F; Weisblum Y; Bao W; George PJ; Rodriguez M; Tricoche N; Schmidt F; Gao C; Jawahar S; Pal M; Schnall E; Zhang H; Strauss D; Yazdanbakhsh K; Hillyer CD; Bieniasz PD; Hatziioannou T
J Clin Microbiol; 2020 Nov; 58(12):. PubMed ID: 32917729
[TBL] [Abstract][Full Text] [Related]
14. Quantitative SARS-CoV-2 Serology in Children With Multisystem Inflammatory Syndrome (MIS-C).
Rostad CA; Chahroudi A; Mantus G; Lapp SA; Teherani M; Macoy L; Tarquinio KM; Basu RK; Kao C; Linam WM; Zimmerman MG; Shi PY; Menachery VD; Oster ME; Edupuganti S; Anderson EJ; Suthar MS; Wrammert J; Jaggi P
Pediatrics; 2020 Dec; 146(6):. PubMed ID: 32879033
[TBL] [Abstract][Full Text] [Related]
15. Serological investigation of asymptomatic cases of SARS-CoV-2 infection reveals weak and declining antibody responses.
Yang Y; Wang X; Du RH; Zhang W; Si HR; Zhu Y; Shen XR; Li Q; Li B; Men D; Zhou YN; Wang H; Tong XL; Zhang XE; Shi ZL; Zhou P
Emerg Microbes Infect; 2021 Dec; 10(1):905-912. PubMed ID: 33870851
[TBL] [Abstract][Full Text] [Related]
16. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19.
Underwood AP; Sølund C; Fernandez-Antunez C; Villadsen SL; Winckelmann AA; Bollerup S; Mikkelsen LS; Sørensen AL; Feng S; Fahnøe U; Lassauniere R; Fomsgaard A; Ramirez S; Weis N; Bukh J
EBioMedicine; 2021 Sep; 71():103519. PubMed ID: 34419923
[TBL] [Abstract][Full Text] [Related]
17. Seroprevalence Surveys for Anti-SARS-CoV-2 Antibody in Different Populations in Taiwan With Low Incidence of COVID-19 in 2020 and Severe Outbreaks of SARS in 2003.
Tseng WP; Wu JL; Wu CC; Kuo KT; Lin CH; Chung MY; Lee YF; Yang BJ; Huang CH; Chen SY; Yu CJ; Chen SC; Hsueh PR
Front Immunol; 2021; 12():626609. PubMed ID: 34084161
[TBL] [Abstract][Full Text] [Related]
18. Performance evaluation of Abbott ARCHITECT SARS-CoV-2 IgG immunoassay in comparison with indirect immunofluorescence and virus microneutralization test.
Meschi S; Colavita F; Bordi L; Matusali G; Lapa D; Amendola A; Vairo F; Ippolito G; Capobianchi MR; Castilletti C;
J Clin Virol; 2020 Aug; 129():104539. PubMed ID: 32679298
[TBL] [Abstract][Full Text] [Related]
19. Comparative analyses of SARS-CoV-2 binding (IgG, IgM, IgA) and neutralizing antibodies from human serum samples.
Mazzini L; Martinuzzi D; Hyseni I; Benincasa L; Molesti E; Casa E; Lapini G; Piu P; Trombetta CM; Marchi S; Razzano I; Manenti A; Montomoli E
J Immunol Methods; 2021 Feb; 489():112937. PubMed ID: 33253698
[TBL] [Abstract][Full Text] [Related]
20. Detection of SARS-CoV-2 antibodies in pediatric patients: An Iranian referral hospital-based study.
Mamishi S; Esslami GG; Mohammadi M; Abdolsalehi MR; Sadeghi RH; Mahmoudi S; Pourakbari B
Hum Antibodies; 2021; 29(3):217-223. PubMed ID: 34151783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
